LDX Treatment Improves Cognitive Function

A small double-blind placebo-controlled study of lisdexamfetamine dimesylate (LDX, marketed in the U.S. as Vyvanse) showed encouraging results treating cognition in CFS patients (Fukuda criteria) who reported impaired short-term memory and delayed reaction time. LDX is a long-acting psychostimulant approved by FDA for treatment of ADHD. CFS patients treated with the drug demonstrated improved cognition and less pain and fatigue compared to the subjects who received placebo. The author suggests that “LDX may reduce pain by improving individuals’ ability to filter out painful stimuli.” Larger and longer studies are needed to assess the value of this therapy. (Psychiatry Research, Oct. 9, 2012)

Tags: , October 9, 2012